Holen Sie sich die Stockscreener-App
1.19
0.85%
0.01
Affimed N V Aktie (AFMD) Neueste Nachrichten
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed's AFM28 Shows 40% Complete Remission Rate in Hard-to-Treat Leukemia Trial - StockTitan
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Yahoo Finance
Affimed Announces Acimtamig and AlloNK® Combination Granted - GlobeNewswire
Affimed's Cancer Therapy Wins FDA RMAT Status After Striking 83% Response Rate in Lymphoma Trial - StockTitan
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00 - Defense World
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... By GuruFocus - Investing.com Canada
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan
Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday - Defense World
Affimed to Report Third Quarter 2024 Financial Results and Corporate Update on November 14, 2024 - Marketscreener.com
Affimed (AFMD) Scheduled to Post Earnings on Thursday - MarketBeat
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - GlobeNewswire
Affimed (AFMD) Sets Q3 2024 Earnings Call for Nov 14: Immuno-Oncology Updates Ahead | AFMD Stock News - StockTitan
Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):